Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer

被引：0
|
作者：
Gulhati, Pat [1 ]
DePinho, Ronald A. [2 ]
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
NATURE CANCER | 2023年 / 4卷 / 01期
关键词：
D O I：
10.1038/s43018-022-00501-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Modulation of T cell immune checkpoints combined with inhibition of chemokine receptors on myeloid-derived suppressor cells can reprogram the highly suppressive tumor immune microenvironment of pancreatic ductal adenocarcinoma (PDAC), and generates durable complete responses in a PDAC mouse model. These results provide a testable clinical regimen for human PDAC.
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [21] Refined strategies for the treatment of pancreatic carcinoma: targeting myeloid cells in order to overcome T cell exhaustion
    Bauer, Christian
    GUT, 2017, 66 (01) : 3 - +
  • [22] Role of Myeloid Derived Suppressor Cells in the Inflammatory Response of Pancreatitis and Pancreatic Cancer
    Rubio, N. E. Cieza
    Heimark, R.
    Jie, T.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S155 - S155
  • [23] Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer
    Bazargan, Sarah
    Bunch, Brittany
    Ojwang', Awino Maureiq E.
    Blauvelt, Jamie
    Landin, Annick
    Ali, Johannes
    Abrahams, Dominique
    Cox, Cheryl
    Hall, Amy M.
    Beatty, Matthew S.
    Poch, Michael
    Rejniak, Katarzyna A.
    Pilon-Thomas, Shari
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] Targeting immune checkpoints on myeloid cells: current status and future directions
    Ma, Chuhan
    Li, Yang
    Li, Min
    Lv, Chao
    Tian, Yu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (02)
  • [25] Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells
    Karakhanova, Svetlana
    Link, Julia
    Heinrich, Moritz
    Shevchenko, Ivan
    Yang, Yuhui
    Hassenpflug, Matthias
    Bunge, Henriette
    von Ahn, Katharina
    Brecht, Ramona
    Mathes, Andreas
    Maier, Caroline
    Umansky, Viktor
    Werner, Jens
    Bazhin, Alexandr V.
    ONCOIMMUNOLOGY, 2015, 4 (04):
  • [26] Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer
    Arina, Ainhoa
    ONCOIMMUNOLOGY, 2014, 3 (04)
  • [27] Therapeutic targeting of myeloid-derived suppressor cells
    Ugel, Stefano
    Delpozzo, Federica
    Desantis, Giacomo
    Papalini, Francesca
    Simonato, Francesca
    Sonda, Nada
    Zilio, Serena
    Bronte, Vincenzo
    CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (04) : 470 - 481
  • [28] Chemotherapeutic targeting of myeloid-derived suppressor cells
    Alizadeh, Darya
    Katsanis, Emmanuel
    Larmonier, Nicolas
    ONCOIMMUNOLOGY, 2014, 3 (01)
  • [29] Myeloid suppressor cells in cancer and autoimmunity
    Sica, Antonio
    Massarotti, Marco
    JOURNAL OF AUTOIMMUNITY, 2017, 85 : 117 - 125
  • [30] Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
    Gulhati, Pat
    Schalck, Aislyn
    Jiang, Shan
    Shang, Xiaoying
    Wu, Chang-Jiun
    Hou, Pingping
    Ruiz, Sharia Hernandez
    Soto, Luisa Solis
    Parra, Edwin
    Ying, Haoqiang
    Han, Jincheng
    Dey, Prasenjit
    Li, Jun
    Deng, Pingna
    Sei, Emi
    Maeda, Dean Y.
    Zebala, John A.
    Spring, Denise J.
    Kim, Michael
    Wang, Huamin
    Maitra, Anirban
    Moore, Dirk
    Clise-Dwyer, Karen
    Wang, Y. Alan
    Navin, Nicholas E.
    DePinho, Ronald A.
    NATURE CANCER, 2023, 4 (01) : 62 - +
12345